(CercleFinance.com) – Novavax announced today that Health Canada, the Canadian health authority, has extended the authorization for use of its Covid vaccine, Nuvaxovid, to 12-17 year olds.
‘With the winter surge of COVID-19, it is more important than ever to ensure that adolescents have access to COVID-19 vaccination options, including with Nuvaxovid,’ said Stanley C. Erck, the leader from Novavax.
Heath Canada’s approval is based on data from a phase III trial in 12-17 year olds showing serum efficacy of 79.5%.
In addition, the preliminary data show that the vaccine was generally well tolerated, underlines the laboratory which indicates that the serious adverse effects were “few and distributed in a balanced way between the vaccine and placebo groups”, suggesting that they do not were therefore not associated with Nuvaxovid.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
